Geographic differences in time to culture conversion in liquid media: Tuberculosis trials Consortium Study 28. Culture conversion is delayed in Africa

William R. Mac Kenzie, Charles M. Heilig, Lorna Bozeman, John L. Johnson, Grace Muzanye, Denise Dunbar, Kenneth C. Jost, Lois Diem, Beverly Metchock, Kathleen Eisenach, Susan Dorman, Stefan Goldberg

Research output: Contribution to journalArticlepeer-review

29 Scopus citations


Background: Tuberculosis Trials Consortium Study 28, was a double blind, randomized, placebo-controlled, phase 2 clinical trial examining smear positive pulmonary Mycobacterium tuberculosis. Over the course of intensive phase therapy, patients from African sites had substantially delayed and lower rates of culture conversion to negative in liquid media compared to non-African patients. We explored potential explanations of this finding. Methods: In TBTC Study 28, protocol-correct patients (n = 328) provided spot sputum specimens for M. tuberculosis culture in liquid media, at baseline and weeks 2, 4, 6 and 8 of study therapy. We compared sputum culture conversion for African and non-African patients stratified by four baseline measures of disease severity: AFB smear quantification, extent of disease on chest radiograph, cavity size and the number of days to detection of M. tuberculosis in liquid media using the Kaplan-Meier product-limit method. We evaluated specimen processing and culture procedures used at 29 study laboratories serving 27 sites. Results: African TB patients had more extensive disease at enrollment than non-African patients. However, African patients with the least disease by the 4 measures of disease severity had conversion rates on liquid media that were substantially lower than conversion rates in non-African patients with the greatest extent of disease. HIV infection, smoking and diabetes did not explain delayed conversion in Africa. Some inter-site variation in laboratory processing and culture procedures within accepted practice for clinical diagnostic laboratories was found. Conclusions: Compared with patients from non-African sites, African patients being treated for TB had delayed sputum culture conversion and lower sputum conversion rates in liquid media that were not explained by baseline severity of disease, HIV status, age, smoking, diabetes or race. Further investigation is warranted into whether modest variation in laboratory processes substantially influences the efficacy outcomes of phase 2 TB treatment trials or if other factors (e.g., nutrition, host response) are involved. Trial Registration: NCT00144417.

Original languageEnglish (US)
Article numbere18358
JournalPloS one
Issue number4
StatePublished - 2011
Externally publishedYes

ASJC Scopus subject areas

  • General


Dive into the research topics of 'Geographic differences in time to culture conversion in liquid media: Tuberculosis trials Consortium Study 28. Culture conversion is delayed in Africa'. Together they form a unique fingerprint.

Cite this